| Host: |
Mouse |
| Applications: |
IHC-P |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Mouse monoclonal antibody anti-TIA is suitable for use in Immunohistochemistry research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
2G9A10F5 |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG1 |
| Formulation: |
Liquid purified Ascites, purified with Protein G Chromatography with 15mM Sodium Azide |
| Purification: |
Purified |
| Dilution Range: |
IHC-P 1:100-1:200 |
| Storage Instruction: |
Store at 2-8°C upon receipt. |
| Immunogen: |
Human bone marrow malignant cells from a non-B, non-T acute leukemia |
| Background | Originally, the 2G9 monoclonal antibody (mAb) was described as identifying a 15 kDa protein found in the cytoplasmic granules of cytotoxic T cells that might be part of a larger 40 kDa molecule, ubiquitously expressed, named p40-TIA-1 and often referred to as TIA-1 in the literature (1, 2). Now, however, there is evidence that the 2G9 mAb identifies a 17 kDa cytoplasmic granule membrane protein named GMP-17 that has no similarity with p40-TIA-1 (3). The GMP-17 antigen is a 165 amino acid protein with 4 transmembrane domains: but it is not a typical member of the fourtransmembrane superfamily. It is identical with previously identified cytotoxic granule proteins called NKG7 and GIG-1 – for GCSF induced gene protein 1 –, isolated from NK cells and granulocyte-colony-stimulatingfactor-treated mononuclear cells, respectively (4, 5). Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended. Control tissue Tonsil. Staining granular |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
